North Immunology Goes Public via Aethlon Merger, Raises $180M for Eczema Drug
- North Immunology, incubated for two years inside hedge fund ADAR1 Capital Management, is going public via a reverse merger with Nasdaq-listed Aethlon Medical, trading as North Immunology under new ticker "NRTX"; Aethlon holders keep about 4.75%.
- Lead asset NOR-101 is a half-life-extended bispecific antibody targeting IL-13 and IL-18, being developed for atopic dermatitis (eczema) as a potential next-generation competitor to Dupixent.
- The deal includes a $180 million PIPE financing from investors such as Bain Capital, Janus Henderson, and Deep Track Capital, funding operations into the second half of 2028.
- Phase 1a is planned for early 2027, with interim PK/safety data by mid-2027 and Phase 1b/2b topline results in 2028.
The reverse-merger-plus-PIPE playbook is becoming the default exit ramp for well-capitalized private biotechs in a still-tepid IPO market — expect more of these Nasdaq-shell conversions through 2026 as sponsors sidestep the pricing risk of a traditional roadshow. More interesting is the origin story: ADAR1 Capital incubating NOR-101 in-house for two years before spinning it out is a hedge fund acting like a venture creator, not just a stock-picker — a build-then-monetize model worth watching as more crossover funds chase asset-level returns. Going after IL-13/IL-18 dual blockade puts North squarely in Dupixent's shadow; differentiated mechanism aside, atopic dermatitis is already crowded (Amgen's rocatinlimab, Sanofi/Regeneron's own follow-ons), so competitive execution and pricing power at launch will matter more than novelty. With Phase 1a not starting until 2027, there's no near-term catalyst — this is a story investors have to hold through, not trade around.
North Immunology goes public via reverse merger as eczema drug heads toward clinic ↗